

Angelo Ravelli

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2230688/publications.pdf>

Version: 2024-02-01

343
papers

23,924
citations

8181

76
h-index

9589

142
g-index

358
all docs

358
docs citations

358
times ranked

12500
citing authors

#	ARTICLE	IF	CITATIONS
1	Juvenile idiopathic arthritis. Lancet, The, 2007, 369, 767-778.	13.7	1,426
2	Preliminary definition of improvement in juvenile arthritis. Arthritis and Rheumatism, 1997, 40, 1202-1209.	6.7	922
3	Randomized Trial of Tocilizumab in Systemic Juvenile Idiopathic Arthritis. New England Journal of Medicine, 2012, 367, 2385-2395.	27.0	716
4	EULAR/PReS endorsed consensus criteria for the classification of childhood vasculitides. Annals of the Rheumatic Diseases, 2005, 65, 936-941.	0.9	659
5	Development and validation of a composite disease activity score for juvenile idiopathic arthritis. Arthritis and Rheumatism, 2009, 61, 658-666.	6.7	579
6	On the Alert for Cytokine Storm: Immunopathology in COVID-19. Arthritis and Rheumatology, 2020, 72, 1059-1063.	5.6	562
7	2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Arthritis and Rheumatology, 2016, 68, 566-576.	5.6	427
8	A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis and Rheumatism, 2007, 56, 3096-3106.	6.7	373
9	Preliminary diagnostic guidelines for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. Journal of Pediatrics, 2005, 146, 598-604.	1.8	365
10	The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. Arthritis and Rheumatism, 2008, 58, 1505-1515.	6.7	346
11	2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis. Annals of the Rheumatic Diseases, 2016, 75, 481-489.	0.9	338
12	Correlation of Serum Interleukin-6 Levels with Joint Involvement and Thrombocytosis in Systemic Juvenile Rheumatoid Arthritis. Arthritis and Rheumatism, 1991, 34, 1158-1163.	6.7	325
13	Clinical Features, Treatment, and Outcome of Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A Multinational, Multicenter Study of 362 Patients. Arthritis and Rheumatology, 2014, 66, 3160-3169.	5.6	322
14	Macrophage activation syndrome as part of systemic juvenile idiopathic arthritis: diagnosis, genetics, pathophysiology and treatment. Genes and Immunity, 2012, 13, 289-298.	4.1	318
15	Toward New Classification Criteria for Juvenile Idiopathic Arthritis: First Steps, Pediatric Rheumatology International Trials Organization International Consensus. Journal of Rheumatology, 2019, 46, 190-197.	2.0	318
16	International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease. Rheumatology, 2004, 43, 49-54.	1.9	311
17	Macrophage activation syndrome. Current Opinion in Rheumatology, 2002, 14, 548-552.	4.3	258
18	Macrophage activation syndrome in juvenile systemic lupus erythematosus: A multinational multicenter study of thirty-eight patients. Arthritis and Rheumatism, 2009, 60, 3388-3399.	6.7	231

#	ARTICLE	IF	CITATIONS
19	Methotrexate Withdrawal at 6 vs 12 Months in Juvenile Idiopathic Arthritis in Remission_{title}A Randomized Clinical Trial_{title}. JAMA - Journal of the American Medical Association, 2010, 303, 1266.	7.4	229
20	Elevated circulating levels of interferon- β and interferon- β -induced chemokines characterise patients with macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. Annals of the Rheumatic Diseases, 2017, 76, 166-172.	0.9	222
21	Preliminary core sets of measures for disease activity and damage assessment in juvenile systemic lupus erythematosus and juvenile dermatomyositis. British Journal of Rheumatology, 2003, 42, 1452-1459.	2.3	209
22	Long-term outcome and prognostic factors of juvenile dermatomyositis: A multinational, multicenter study of 490 patients. Arthritis Care and Research, 2010, 62, 63-72.	3.4	207
23	Mutations in the perforin gene can be linked to macrophage activation syndrome in patients with systemic onset juvenile idiopathic arthritis. Rheumatology, 2010, 49, 441-449.	1.9	202
24	Patterns of clinical remission in select categories of juvenile idiopathic arthritis. Arthritis and Rheumatism, 2005, 52, 3554-3562.	6.7	200
25	ADA2 deficiency (DADA2) as an unrecognised cause of early onset polyarteritis nodosa and stroke: a multicentre national study. Annals of the Rheumatic Diseases, 2017, 76, 1648-1656.	0.9	199
26	Patients with antinuclear antibody-“positive juvenile idiopathic arthritis constitute a homogeneous subgroup irrespective of the course of joint disease. Arthritis and Rheumatism, 2005, 52, 826-832.	6.7	197
27	Pediatric Antiphospholipid Syndrome: Clinical and Immunologic Features of 121 Patients in an International Registry. Pediatrics, 2008, 122, e1100-e1107.	2.1	193
28	EULAR recommendations for vaccination in paediatric patients with rheumatic diseases. Annals of the Rheumatic Diseases, 2011, 70, 1704-1712.	0.9	193
29	Systemic sclerosis in childhood: Clinical and immunologic features of 153 patients in an international database. Arthritis and Rheumatism, 2006, 54, 3971-3978.	6.7	189
30	EULAR/PRINTO/PRES criteria for Henoch-Schonlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part I: Overall methodology and clinical characterisation. Annals of the Rheumatic Diseases, 2010, 69, 790-797.	0.9	187
31	Consensus-based recommendations for the management of juvenile dermatomyositis. Annals of the Rheumatic Diseases, 2017, 76, 329-340.	0.9	185
32	Treating juvenile idiopathic arthritis to target: recommendations of an international task force. Annals of the Rheumatic Diseases, 2018, 77, annrheumdis-2018-213030.	0.9	183
33	Functional and prognostic relevance of the ~ 173 polymorphism of the macrophage migration inhibitory factor gene in systemic-onset juvenile idiopathic arthritis. Arthritis and Rheumatism, 2003, 48, 1398-1407.	6.7	173
34	Remission, minimal disease activity, and acceptable symptom state in juvenile idiopathic arthritis: Defining criteria based on the juvenile arthritis disease activity score. Arthritis and Rheumatism, 2012, 64, 2366-2374.	6.7	171
35	Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial. Lancet, The, 2016, 387, 671-678.	13.7	168
36	A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features. Arthritis and Rheumatism, 2012, 64, 557-567.	6.7	167

#	ARTICLE	IF	CITATIONS
37	The Pediatric Rheumatology European Society/American College of Rheumatology/European League against Rheumatism provisional classification criteria for juvenile systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2007, 57, 203-212.	6.7	164
38	A New Approach to Clinical Care of Juvenile Idiopathic Arthritis: The Juvenile Arthritis Multidimensional Assessment Report. <i>Journal of Rheumatology</i> , 2011, 38, 938-953.	2.0	159
39	Comparison of clinical versus ultrasound-determined synovitis in juvenile idiopathic arthritis. <i>Arthritis and Rheumatism</i> , 2009, 61, 1497-1504.	6.7	156
40	Assessment of damage in juvenile-onset systemic lupus erythematosus: A multicenter cohort study. <i>Arthritis and Rheumatism</i> , 2003, 49, 501-507.	6.7	150
41	Juvenile Idiopathic Arthritis: Diagnosis and Treatment. <i>Rheumatology and Therapy</i> , 2016, 3, 187-207.	2.3	148
42	Development and validation of a clinical index for assessment of long-term damage in juvenile idiopathic arthritis. <i>Arthritis and Rheumatism</i> , 2005, 52, 2092-2102.	6.7	142
43	An International Consensus Survey of Diagnostic Criteria for Macrophage Activation Syndrome in Systemic Juvenile Idiopathic Arthritis. <i>Journal of Rheumatology</i> , 2011, 38, 764-768.	2.0	140
44	Antinuclear antibody-positive patients should be grouped as a separate category in the classification of juvenile idiopathic arthritis. <i>Arthritis and Rheumatism</i> , 2011, 63, 267-275.	6.7	140
45	European evidence-based recommendations for diagnosis and treatment of childhood-onset systemic lupus erythematosus: the SHARE initiative. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1788-1796.	0.9	139
46	The provisional Paediatric Rheumatology International Trials Organisation/American College of Rheumatology/european League Against Rheumatism Disease activity core set for the evaluation of response to therapy in juvenile dermatomyositis: A prospective validation study. <i>Arthritis and Rheumatism</i> , 2008, 59, 4-13.	6.7	136
47	Macrophage activation syndrome in systemic juvenile rheumatoid arthritis successfully treated with cyclosporine. <i>Journal of Pediatrics</i> , 1996, 128, 275-278.	1.8	134
48	A proposal for a pediatric version of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index based on the analysis of 1,015 patients with juvenile-onset systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2006, 54, 2989-2996.	6.7	133
49	Clinical outcome measures in juvenile idiopathic arthritis. <i>Pediatric Rheumatology</i> , 2016, 14, 23.	2.1	133
50	Magnetic resonance imaging, ultrasonography, and conventional radiography in the assessment of bone erosions in juvenile idiopathic arthritis. <i>Arthritis and Rheumatism</i> , 2008, 59, 1764-1772.	6.7	126
51	Proxy-reported health-related quality of life of patients with juvenile idiopathic arthritis: The pediatric rheumatology international trials organization multinational quality of life cohort study. <i>Arthritis and Rheumatism</i> , 2007, 57, 35-43.	6.7	121
52	Macrophage Activation Syndrome. <i>Hematology/Oncology Clinics of North America</i> , 2015, 29, 927-941.	2.2	121
53	Phenotypic variability and disparities in treatment and outcomes of childhood arthritis throughout the world: an observational cohort study. <i>The Lancet Child and Adolescent Health</i> , 2019, 3, 255-263.	5.6	120
54	Evaluation of 21-Numbered Circle and 10-Centimeter Horizontal Line Visual Analog Scales for Physician and Parent Subjective Ratings in Juvenile Idiopathic Arthritis. <i>Journal of Rheumatology</i> , 2010, 37, 1534-1541.	2.0	119

#	ARTICLE	IF	CITATIONS
55	Consensus-based recommendations for the management of uveitis associated with juvenile idiopathic arthritis: the SHARE initiative. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, annrheumdis-2018-213131.	0.9	119
56	Defining Criteria for Disease Activity States in Nonsystemic Juvenile Idiopathic Arthritis Based on a Three-Variable Juvenile Arthritis Disease Activity Score. <i>Arthritis Care and Research</i> , 2014, 66, 1703-1709.	3.4	115
57	Safety and efficacy of early high-dose IV anakinra in severe COVID-19 lung disease. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 146, 213-215.	2.9	115
58	Whole-body MRI in the assessment of disease activity in juvenile dermatomyositis. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1083-1090.	0.9	113
59	The PRINTO criteria for clinically inactive disease in juvenile dermatomyositis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 686-693.	0.9	109
60	Damage extent and predictors in adult and juvenile dermatomyositis and polymyositis as determined with the myositis damage index. <i>Arthritis and Rheumatism</i> , 2009, 60, 3425-3435.	6.7	107
61	European evidence-based recommendations for the diagnosis and treatment of childhood-onset lupus nephritis: the SHARE initiative. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1965-1973.	0.9	105
62	Nephrotic-range proteinuria, the major risk factor for early atherosclerosis in juvenile-onset systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2000, 43, 1405-1409.	6.7	103
63	Performance of Current Guidelines for Diagnosis of Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis. <i>Arthritis and Rheumatology</i> , 2014, 66, 2871-2880.	5.6	101
64	Development and validation of a preliminary definition of minimal disease activity in patients with juvenile idiopathic arthritis. <i>Arthritis and Rheumatism</i> , 2008, 59, 1120-1127.	6.7	98
65	Type I interferon pathway activation in COPA syndrome. <i>Clinical Immunology</i> , 2018, 187, 33-36.	3.2	98
66	Effect of Biologic Therapy on Clinical and Laboratory Features of Macrophage Activation Syndrome Associated With Systemic Juvenile Idiopathic Arthritis. <i>Arthritis Care and Research</i> , 2018, 70, 409-419.	3.4	96
67	Development and validation of a new short and simple measure of physical function for juvenile idiopathic arthritis. <i>Arthritis and Rheumatism</i> , 2007, 57, 913-920.	6.7	95
68	Prognostic factors for radiographic progression, radiographic damage, and disability in juvenile idiopathic arthritis. <i>Arthritis and Rheumatism</i> , 2003, 48, 3509-3517.	6.7	93
69	Health-related quality of life in juvenile-onset systemic lupus erythematosus and its relationship to disease activity and damage. <i>Arthritis and Rheumatism</i> , 2004, 51, 458-464.	6.7	93
70	Ultrasound-detected synovial abnormalities are frequent in clinically inactive juvenile idiopathic arthritis, but do not predict a flare of synovitis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 223-228.	0.9	85
71	Efficacy and Adverse Events During Janus Kinase Inhibitor Treatment of SAVI Syndrome. <i>Journal of Clinical Immunology</i> , 2019, 39, 476-485.	3.8	85
72	Performance of the preliminary definition of improvement in juvenile chronic arthritis patients treated with methotrexate. <i>Annals of the Rheumatic Diseases</i> , 1998, 57, 38-41.	0.9	84

#	ARTICLE	IF	CITATIONS
73	The Paediatric Rheumatology International Trials Organisation provisional criteria for the evaluation of response to therapy in juvenile dermatomyositis. <i>Arthritis Care and Research</i> , 2010, 62, 1533-1541.	3.4	84
74	Correlation between conventional disease activity measures in juvenile chronic arthritis. <i>Annals of the Rheumatic Diseases</i> , 1997, 56, 197-200.	0.9	83
75	Adapted versions of the Sharp/van der Heijde score are reliable and valid for assessment of radiographic progression in juvenile idiopathic arthritis. <i>Arthritis and Rheumatism</i> , 2007, 56, 3087-3095.	6.7	80
76	Defining Kawasaki disease and pediatric inflammatory multisystem syndrome-temporally associated to SARS-CoV-2 infection during SARS-CoV-2 epidemic in Italy: results from a national, multicenter survey. <i>Pediatric Rheumatology</i> , 2021, 19, 29.	2.1	78
77	Outcome in juvenile onset systemic lupus erythematosus. <i>Current Opinion in Rheumatology</i> , 2005, 17, 568-573.	4.3	77
78	The Pediatric Rheumatology International Trials Organization criteria for the evaluation of response to therapy in juvenile systemic lupus erythematosus: Prospective validation of the disease activity core set. <i>Arthritis and Rheumatism</i> , 2005, 52, 2854-2864.	6.7	77
79	Defining criteria for high disease activity in juvenile idiopathic arthritis based on the Juvenile Arthritis Disease Activity Score. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1380-1383.	0.9	77
80	European consensus-based recommendations for the diagnosis and treatment of rare paediatric vasculitides – the SHARE initiative. <i>Rheumatology</i> , 2019, 58, 656-671.	1.9	77
81	Neutrophil Extracellular Traps Profiles in Patients with Incident Systemic Lupus Erythematosus and Lupus Nephritis. <i>Journal of Rheumatology</i> , 2020, 47, 377-386.	2.0	77
82	Methotrexate in juvenile idiopathic arthritis: advice and recommendations from the MARAJIA expert consensus meeting. <i>Pediatric Rheumatology</i> , 2018, 16, 46.	2.1	76
83	Relationship between Damage Accrual, Disease Flares and Cumulative Drug Therapies in Juvenile-Onset Systemic Lupus Erythematosus. <i>Lupus</i> , 2006, 15, 515-520.	1.6	75
84	European evidence-based recommendations for diagnosis and treatment of paediatric antiphospholipid syndrome: the SHARE initiative. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1637-1641.	0.9	75
85	Cross-cultural adaptation and psychometric evaluation of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) in 54 languages across 52 countries: review of the general methodology. <i>Rheumatology International</i> , 2018, 38, 5-17.	3.0	74
86	Development and initial validation of the MS score for diagnosis of macrophage activation syndrome in systemic juvenile idiopathic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1357-1362.	0.9	74
87	Advances and challenges in imaging in juvenile idiopathic arthritis. <i>Nature Reviews Rheumatology</i> , 2012, 8, 329-336.	8.0	73
88	The Pediatric Rheumatology International Trials Organization/American College of Rheumatology provisional criteria for the evaluation of response to therapy in juvenile systemic lupus erythematosus: Prospective validation of the definition of improvement. <i>Arthritis and Rheumatism</i> , 2006, 55, 355-363.	6.7	72
89	Parent and Child Acceptable Symptom State in Juvenile Idiopathic Arthritis. <i>Journal of Rheumatology</i> , 2012, 39, 856-863.	2.0	72
90	Evidence-based diagnosis and treatment of macrophage activation syndrome in systemic juvenile idiopathic arthritis. <i>Pediatric Rheumatology</i> , 2015, 13, 55.	2.1	72

#	ARTICLE	IF	CITATIONS
91	Anticardiolipin Antibodies in Pediatric Systemic Lupus Erythematosus. JAMA Pediatrics, 1994, 148, 398.	3.0	71
92	Marked and sustained improvement two years after autologous stem cell transplantation in a girl with systemic sclerosis. Arthritis and Rheumatism, 1999, 42, 807-811.	6.7	71
93	Factors affecting survival in juvenile systemic sclerosis. Rheumatology, 2009, 48, 119-122.	1.9	71
94	ANTIPHOSPHOLIPID ANTIBODY SYNDROME IN PEDIATRIC PATIENTS. Rheumatic Disease Clinics of North America, 1997, 23, 657-676.	1.9	70
95	Level of agreement between children, parents, and physicians in rating pain intensity in juvenile idiopathic arthritis. Arthritis and Rheumatism, 2006, 55, 177-183.	6.7	70
96	Seeking insights into the EPidemiology, treatment and Outcome of Childhood Arthritis through a multinational collaborative effort: Introduction of the EPOCA study. Pediatric Rheumatology, 2012, 10, 39.	2.1	70
97	Dynamic contrast-enhanced magnetic resonance imaging in the assessment of disease activity in patients with juvenile idiopathic arthritis. Rheumatology, 2010, 49, 178-185.	1.9	69
98	Development of the autoinflammatory disease damage index (ADDI). Annals of the Rheumatic Diseases, 2017, 76, 821-830.	0.9	68
99	Childhood multisystem inflammatory syndrome associated with COVID-19 (MIS-C): a diagnostic and treatment guidance from the Rheumatology Study Group of the Italian Society of Pediatrics. Italian Journal of Pediatrics, 2021, 47, 24.	2.6	68
100	Macrophage migration inhibitory factor in patients with juvenile idiopathic arthritis. Arthritis and Rheumatism, 2002, 46, 232-237.	6.7	67
101	The magnitude of early response to methotrexate therapy predicts long-term outcome of patients with juvenile idiopathic arthritis. Annals of the Rheumatic Diseases, 2007, 67, 370-374.	0.9	67
102	Intravenous iron therapy for severe anaemia in systemic-onset juvenile chronic arthritis. Lancet, The, 1994, 344, 1052-1054.	13.7	63
103	Neurological Disorders, other than Stroke, Associated with Antiphospholipid Antibodies in Childhood. Neuropediatrics, 1996, 27, 149-153.	0.6	63
104	Outcome of primary antiphospholipid syndrome in childhood. Lupus, 2003, 12, 449-453.	1.6	63
105	Review: Macrophage activation syndrome in juvenile systemic lupus erythematosus: an under-recognized complication?. Lupus, 2007, 16, 587-592.	1.6	63
106	Multi-antibody composition in lupus nephritis: Isotype and antigen specificity make the difference. Autoimmunity Reviews, 2015, 14, 692-702.	5.8	63
107	Use of the sharp and larsen scoring methods in the assessment of radiographic progression in juvenile idiopathic arthritis. Arthritis and Rheumatism, 2006, 55, 717-723.	6.7	61
108	Achievement of a State of Inactive Disease at Least Once in the First 5 Years Predicts Better Outcome of Patients with Polyarticular Juvenile Idiopathic Arthritis. Journal of Rheumatology, 2009, 36, 628-634.	2.0	61

#	ARTICLE	IF	CITATIONS
109	Efficacy of early anti-inflammatory treatment with high doses of intravenous anakinra with or without glucocorticoids in patients with severe COVID-19 pneumonia. Journal of Allergy and Clinical Immunology, 2021, 147, 1217-1225.	2.9	61
110	Development and preliminary validation of a paediatric-targeted MRI scoring system for the assessment of disease activity and damage in juvenile idiopathic arthritis. Annals of the Rheumatic Diseases, 2011, 70, 440-446.	0.9	60
111	Clinical features and correct diagnosis of macrophage activation syndrome. Expert Review of Clinical Immunology, 2015, 11, 1043-1053.	3.0	60
112	Outcome and predicting factors of single and multiple intra-articular corticosteroid injections in children with juvenile idiopathic arthritis. Rheumatology, 2011, 50, 1627-1634.	1.9	59
113	Dissecting the Heterogeneity of Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis. Journal of Rheumatology, 2015, 42, 994-1001.	2.0	59
114	2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Arthritis and Rheumatology, 2017, 69, 911-923.	5.6	59
115	Radiologic progression in patients with juvenile chronic arthritis treated with methotrexate. Journal of Pediatrics, 1998, 133, 262-265.	1.8	58
116	The extended oligoarticular subtype is the best predictor of methotrexate efficacy in juvenile idiopathic arthritis. Journal of Pediatrics, 1999, 135, 316-320.	1.8	57
117	Vaccination in paediatric patients with auto-immune rheumatic diseases: A systemic literature review for the European League against Rheumatism evidence-based recommendations. Autoimmunity Reviews, 2011, 11, 112-122.	5.8	57
118	Improving inflammatory arthritis management through tighter monitoring of patients and the use of innovative electronic tools. RMD Open, 2016, 2, e000302.	3.8	57
119	Expert consensus on dynamics of laboratory tests for diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. RMD Open, 2016, 2, e000161.	3.8	57
120	Hypocomplementemic urticarial vasculitis syndrome with severe systemic manifestations. Journal of Pediatrics, 1994, 124, 742-744.	1.8	56
121	Self epitopes shared between human skeletal myosin and Streptococcus pyogenes M5 protein are targets of immune responses in active juvenile dermatomyositis. Arthritis and Rheumatism, 2002, 46, 3015-3025.	6.7	55
122	Methotrexate improves the health-related quality of life of children with juvenile idiopathic arthritis. Annals of the Rheumatic Diseases, 2007, 67, 309-314.	0.9	55
123	Measures of disease activity and damage in paediatric systemic lupus erythematosus: British Isles Lupus Assessment Group (BILAG), European Consensus Lupus Activity Measurement (ECLAM), Systemic Lupus Activity Measure (SLAM), Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), Physician's Global Assessment of Disease Activity (MD Global), and Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SLICC/ACR DI: SDI). Arthritis Care and Research, 2011, 63, S112-7.	3.4	55
124	A longitudinal PRINTO study on growth and puberty in juvenile systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2012, 71, 511-517.	0.9	55
125	Muscle Expression of Type I and Type II Interferons Is Increased in Juvenile Dermatomyositis and Related to Clinical and Histologic Features. Arthritis and Rheumatology, 2019, 71, 1011-1021.	5.6	55
126	The Ped-APS Registry: the antiphospholipid syndrome in childhood. Lupus, 2009, 18, 894-899.	1.6	54

#	ARTICLE	IF	CITATIONS
127	Methotrexate Therapy May Prevent the Onset of Uveitis in Juvenile Idiopathic Arthritis. Journal of Pediatrics, 2013, 163, 879-884.	1.8	54
128	Immune responses to the Escherichia coli dnaJ heat shock protein in juvenile rheumatoid arthritis and their correlation with disease activity. Journal of Pediatrics, 1994, 124, 561-565.	1.8	52
129	Assessing current outcomes of juvenile idiopathic arthritis: A cross-sectional study in a tertiary center sample. Arthritis and Rheumatism, 2008, 59, 1571-1579.	6.7	52
130	Intra-articular corticosteroids versus intra-articular corticosteroids plus methotrexate in oligoarticular juvenile idiopathic arthritis: a multicentre, prospective, randomised, open-label trial. Lancet, The, 2017, 389, 909-916.	13.7	52
131	2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Adult Dermatomyositis and Polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Arthritis and Rheumatology, 2017, 69, 898-910.	5.6	52
132	Temporomandibular Joint Involvement in Association With Quality of Life, Disability, and High Disease Activity in Juvenile Idiopathic Arthritis. Arthritis Care and Research, 2017, 69, 677-686.	3.4	52
133	Prevalence of anticardiolipin antibodies in juvenile chronic arthritis.. Annals of the Rheumatic Diseases, 1991, 50, 599-601.	0.9	51
134	2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis. Annals of the Rheumatic Diseases, 2017, 76, 782-791.	0.9	51
135	Development and Initial Validation of the Macrophage Activation Syndrome/Primary Hemophagocytic Lymphohistiocytosis Score, a Diagnostic Tool that Differentiates Primary Hemophagocytic Lymphohistiocytosis from Macrophage Activation Syndrome. Journal of Pediatrics, 2017, 189, 72-78.e3.	1.8	50
136	Treatment of Takayasu's Arteritis with Tumor Necrosis Factor Antagonists. Journal of Pediatrics, 2008, 153, 432-434.	1.8	49
137	Update on the pathogenesis and treatment of juvenile idiopathic arthritis. Current Opinion in Rheumatology, 2017, 29, 523-529.	4.3	49
138	Developing outcome measures for paediatric rheumatic diseases. Best Practice and Research in Clinical Rheumatology, 2009, 23, 609-624.	3.3	47
139	Therapeutic approaches in the treatment of juvenile dermatomyositis in patients with recent-onset disease and in those experiencing disease flare: An international multicenter PRINTO study. Arthritis and Rheumatism, 2011, 63, 3142-3152.	6.7	47
140	Ferritin to Erythrocyte Sedimentation Rate Ratio: Simple Measure to Identify Macrophage Activation Syndrome in Systemic Juvenile Idiopathic Arthritis. ACR Open Rheumatology, 2019, 1, 345-349.	2.1	47
141	Predictors of poor response to methotrexate in polyarticular-course juvenile idiopathic arthritis: analysis of the PRINTO methotrexate trial. Annals of the Rheumatic Diseases, 2010, 69, 1479-1483.	0.9	46
142	Health-related quality of life of patients with juvenile dermatomyositis: Results from the paediatric rheumatology international trials organisation multinational quality of life cohort study. Arthritis and Rheumatism, 2009, 61, 509-517.	6.7	45
143	Cytokines in juvenile rheumatoid arthritis. Current Opinion in Rheumatology, 1997, 9, 428-433.	4.3	44
144	Correlation between juvenile idiopathic arthritis activity and damage measures in early, advanced, and longstanding disease. Arthritis and Rheumatism, 2006, 55, 843-849.	6.7	44

#	ARTICLE	IF	CITATIONS
145	Consensus procedures and their role in pediatric rheumatology. <i>Current Rheumatology Reports</i> , 2008, 10, 142-146.	4.7	44
146	Preliminary validation of clinical remission criteria using the OMERACT filter for select categories of juvenile idiopathic arthritis. <i>Journal of Rheumatology</i> , 2006, 33, 789-95.	2.0	44
147	Factors Associated with Achievement of Inactive Disease in Children with Juvenile Idiopathic Arthritis Treated with Etanercept. <i>Journal of Rheumatology</i> , 2013, 40, 192-200.	2.0	43
148	Towards a role of ultrasound in children with juvenile idiopathic arthritis. <i>Rheumatology</i> , 2013, 52, 413-420.	1.9	43
149	Antiphospholipid Syndrome. <i>Pediatric Clinics of North America</i> , 2005, 52, 469-491.	1.8	42
150	Predictors of Effectiveness of Anakinra in Systemic Juvenile Idiopathic Arthritis. <i>Journal of Rheumatology</i> , 2019, 46, 416-421.	2.0	41
151	Preliminary definition of improvement in juvenile arthritis. <i>Arthritis and Rheumatism</i> , 1997, 40, 1202-1209.	6.7	40
152	Development and Testing of Reduced Joint Counts in Juvenile Idiopathic Arthritis. <i>Journal of Rheumatology</i> , 2009, 36, 183-190.	2.0	40
153	A new short and simple health-related quality of life measurement for paediatric rheumatic diseases: initial validation in juvenile idiopathic arthritis. <i>Rheumatology</i> , 2010, 49, 1272-1280.	1.9	39
154	IL-1 Inhibition in Systemic Juvenile Idiopathic Arthritis. <i>Frontiers in Pharmacology</i> , 2016, 7, 467.	3.5	39
155	Development and initial validation of a composite disease activity score for systemic juvenile idiopathic arthritis. <i>Rheumatology</i> , 2020, 59, 3505-3514.	1.9	39
156	Delineating the Role of Multiple Intraarticular Corticosteroid Injections in the Management of Juvenile Idiopathic Arthritis in the Biologic Era. <i>Arthritis Care and Research</i> , 2013, 65, 1112-1120.	3.4	38
157	Discordance between physician's and parent's global assessments in juvenile idiopathic arthritis. <i>Rheumatology</i> , 2007, 46, 141-145.	1.9	37
158	Advances in biomarkers for paediatric rheumatic diseases. <i>Nature Reviews Rheumatology</i> , 2015, 11, 265-275.	8.0	37
159	Disease activity and damage in juvenile idiopathic arthritis: methotrexate era versus biologic era. <i>Arthritis Research and Therapy</i> , 2019, 21, 168.	3.5	37
160	MRI versus conventional measures of disease activity and structural damage in evaluating treatment efficacy in juvenile idiopathic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 363-368.	0.9	36
161	Development of a consensus core dataset in juvenile dermatomyositis for clinical use to inform research. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 241-250.	0.9	36
162	Next generation sequencing panel in undifferentiated autoinflammatory diseases identifies patients with colchicine-responder recurrent fevers. <i>Rheumatology</i> , 2020, 59, 344-360.	1.9	36

#	ARTICLE	IF	CITATIONS
163	Recurrent juvenile dermatomyositis and cutaneous necrotizing arteritis with molecular mimicry between streptococcal type 5 M protein and human skeletal myosin. <i>Journal of Pediatrics</i> , 1992, 121, 739-742.	1.8	35
164	Relative responsiveness of condition specific and generic health status measures in juvenile idiopathic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2005, 64, 257-261.	0.9	35
165	Development and Initial Validation of a Radiographic Scoring System for the Hip in Juvenile Idiopathic Arthritis. <i>Journal of Rheumatology</i> , 2010, 37, 432-439.	2.0	35
166	Disease status, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etanercept. <i>Pediatric Rheumatology</i> , 2016, 14, 68.	2.1	35
167	Responsiveness of outcome measures in juvenile chronic arthritis. Italian Pediatric Rheumatology Study Group. <i>British Journal of Rheumatology</i> , 1999, 38, 176-180.	2.3	34
168	A longitudinal analysis of physical functional disability over the course of juvenile idiopathic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2008, 67, 1159-1164.	0.9	34
169	Inactive disease and remission in childhood-onset systemic lupus erythematosus. <i>Arthritis Care and Research</i> , 2012, 64, 683-693.	3.4	34
170	Establishing an Updated Core Domain Set for Studies in Juvenile Idiopathic Arthritis: A Report from the OMERACT 2018 JIA Workshop. <i>Journal of Rheumatology</i> , 2019, 46, 1006-1013.	2.0	34
171	Comparison of clinical features and drug therapies among European and Latin American patients with juvenile dermatomyositis. <i>Clinical and Experimental Rheumatology</i> , 2011, 29, 117-24.	0.8	34
172	Toward a treat-to-target approach in the management of juvenile idiopathic arthritis. <i>Clinical and Experimental Rheumatology</i> , 2012, 30, S157-62.	0.8	34
173	Antiphospholipid antibody associated thrombosis in juvenile chronic arthritis.. <i>Archives of Disease in Childhood</i> , 1992, 67, 1384-1385.	1.9	33
174	Validation of the Childhood Health Assessment Questionnaire in active juvenile systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2008, 59, 1112-1119.	6.7	33
175	Definition and Validation of the American College of Rheumatology 2021 Juvenile Arthritis Disease Activity Score—Cutoffs for Disease Activity States in Juvenile Idiopathic Arthritis. <i>Arthritis and Rheumatology</i> , 2021, 73, 1966-1975.	5.6	33
176	Antiphospholipid Syndrome in Pediatrics. <i>Rheumatic Disease Clinics of North America</i> , 2007, 33, 499-523.	1.9	32
177	Antiphospholipid antibodies in paediatrics. <i>European Journal of Pediatrics</i> , 1994, 153, 472-479.	2.7	31
178	Revised recommendations of the Italian Society of Pediatrics about the general management of Kawasaki disease. <i>Italian Journal of Pediatrics</i> , 2021, 47, 16.	2.6	31
179	Physicians' and parents' ratings of inactive disease are frequently discordant in juvenile idiopathic arthritis. <i>Journal of Rheumatology</i> , 2007, 34, 1773-6.	2.0	30
180	Systemic lupus erythematosus with jaccoud's arthropathy mimicking juvenile rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1987, 30, 1062-1064.	6.7	29

#	ARTICLE	IF	CITATIONS
181	Preliminary criteria for global flares in childhood-onset systemic lupus erythematosus. <i>Arthritis Care and Research</i> , 2011, 63, 1213-1223.	3.4	28
182	Measuring Disease Damage and Its Severity in Childhood-Onset Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2018, 70, 1621-1629.	3.4	28
183	Serum level of KL-6 as a marker of interstitial lung disease in patients with juvenile systemic sclerosis. <i>Journal of Rheumatology</i> , 2004, 31, 795-800.	2.0	28
184	Course of joint disease in patients with antinuclear antibody-positive juvenile idiopathic arthritis. <i>Journal of Rheumatology</i> , 2005, 32, 1805-10.	2.0	28
185	The conundrum of juvenile psoriatic arthritis. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, S40-3.	0.8	28
186	The Clinical Significance of Antiphospholipid Antibodies. <i>Annals of Medicine</i> , 1997, 29, 159-163.	3.8	27
187	Positive family history of psoriasis does not affect the clinical expression and course of juvenile idiopathic arthritis patients with oligoarthritis. <i>Arthritis and Rheumatism</i> , 2003, 49, 488-493.	6.7	27
188	Development and initial validation of composite parent- and child-centered disease assessment indices for juvenile idiopathic arthritis. <i>Arthritis Care and Research</i> , 2011, 63, 1262-1270.	3.4	27
189	In silico validation of the Autoinflammatory Disease Damage Index. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1599-1605.	0.9	27
190	Timely Recognition and Early Multi-Step Antinflammatory Therapy May Prevent ICU Admission of Patients With MIS-C: Proposal for a Severity Score. <i>Frontiers in Pediatrics</i> , 2021, 9, 783745.	1.9	26
191	CACP syndrome: identification of five novel mutations and of the first case of UPD in the largest European cohort. <i>European Journal of Human Genetics</i> , 2014, 22, 197-201.	2.8	25
192	Female Sex and Oligoarthritis Category Are Not Risk Factors for Uveitis in Italian Children with Juvenile Idiopathic Arthritis. <i>Journal of Rheumatology</i> , 2014, 41, 1416-1425.	2.0	25
193	Neutrophil Extracellular Traps in the Autoimmunity Context. <i>Frontiers in Medicine</i> , 2021, 8, 614829.	2.6	25
194	The time has come to include assessment of radiographic progression in juvenile idiopathic arthritis clinical trials. <i>Journal of Rheumatology</i> , 2008, 35, 553-7.	2.0	25
195	Evaluation of response to methotrexate by a functional index in juvenile chronic arthritis. <i>Clinical Rheumatology</i> , 1995, 14, 322-326.	2.2	24
196	Criteria to define response to therapy in paediatric rheumatic diseases. <i>European Journal of Clinical Pharmacology</i> , 2011, 67, 125-131.	1.9	24
197	Multisystem Inflammatory Syndrome in Children: Unique Disease or Part of the Kawasaki Disease Spectrum?. <i>Frontiers in Pediatrics</i> , 2021, 9, 680813.	1.9	24
198	Review: The Paediatric Rheumatology International Trials Organization (PRINTO). <i>Lupus</i> , 2007, 16, 670-676.	1.6	23

#	ARTICLE	IF	CITATIONS
199	EULAR/PRES recommendations for vaccination of paediatric patients with autoimmune inflammatory rheumatic diseases: update 2021. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, 35-47.	0.9	23
200	Clinical assessment in juvenile dermatomyositis. <i>Autoimmunity</i> , 2006, 39, 197-203.	2.6	22
201	HRCT and pulmonary function tests in monitoring of lung involvement in juvenile systemic sclerosis. <i>Pediatric Pulmonology</i> , 2009, 44, 1226-1234.	2.0	22
202	Delineating the Application of Ultrasound in Detecting Synovial Abnormalities of the Subtalar Joint in Juvenile Idiopathic Arthritis. <i>Arthritis Care and Research</i> , 2016, 68, 1346-1353.	3.4	22
203	Defining criteria for disease activity states in juvenile idiopathic arthritis: Table 1. <i>Rheumatology</i> , 2016, 55, 595-596.	1.9	22
204	Kawasaki disease or Kawasaki syndrome?. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 993-995.	0.9	22
205	Management of adult-onset Still's disease with interleukin-1 inhibitors: evidence- and consensus-based statements by a panel of Italian experts. <i>Arthritis Research and Therapy</i> , 2019, 21, 275.	3.5	20
206	Wegener Granulomatosis in a Child: Cutaneous Findings as the Presenting Signs. <i>Pediatric Dermatology</i> , 1999, 16, 277-280.	0.9	19
207	American College of Rheumatology Provisional Criteria for Global Flares in Childhood-Onset Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2018, 70, 813-822.	3.4	19
208	Development and Testing of a Hybrid Measure of Muscle Strength in Juvenile Dermatomyositis for Use in Routine Care. <i>Arthritis Care and Research</i> , 2018, 70, 1312-1319.	3.4	19
209	IgA Nephropathy and Henoch-Schönlein Syndrome Occurring in the Same Patient. <i>Nephron</i> , 1996, 72, 111-112.	1.8	18
210	Marked and sustained improvement 2 years after autologous stem cell transplantation in a girl with systemic sclerosis. <i>Rheumatology</i> , 1999, 38, 773-773.	1.9	17
211	Development of an internationally agreed minimal dataset for juvenile dermatomyositis (JDM) for clinical and research use. <i>Trials</i> , 2015, 16, 268.	1.6	17
212	Disparities in the prevalence of clinical features between systemic juvenile idiopathic arthritis and adult-onset Still's disease. <i>Rheumatology</i> , 2022, 61, 4124-4129.	1.9	16
213	Frequency of Autoantibodies in Normal Children. <i>JAMA Pediatrics</i> , 1989, 143, 493.	3.0	15
214	Pulmonary function in children with systemic lupus erythematosus.. <i>Thorax</i> , 1996, 51, 424-428.	5.6	15
215	Juvenile Idiopathic Arthritis. <i>BioDrugs</i> , 2000, 14, 93-98.	4.6	15
216	Novel automated system for magnetic resonance imaging quantification of the inflamed synovial membrane volume in patients with juvenile idiopathic arthritis. <i>Arthritis Care and Research</i> , 2012, 64, 1657-1664.	3.4	15

#	ARTICLE	IF	CITATIONS
217	Unraveling the Phenotypic Variability of Juvenile Idiopathic Arthritis across Races or Geographic Areas â€” Key to Understanding Etiology and Genetic Factors?. Journal of Rheumatology, 2016, 43, 683-685.	2.0	15
218	The European network for care of children with paediatric rheumatic diseases: care across borders. Rheumatology, 2019, 58, 1188-1195.	1.9	15
219	American College of Rheumatology Provisional Criteria for Clinically Relevant Improvement in Children and Adolescents With Childhoodâ€™Onset Systemic Lupus Erythematosus. Arthritis Care and Research, 2019, 71, 579-590.	3.4	15
220	Toward the Development of New Diagnostic Criteria for Macrophage Activation Syndrome in Systemic Juvenile Idiopathic Arthritis. Annals of Paediatric Rheumatology, 2012, 1, 1.	0.0	15
221	Methotrexate hepatotoxic effects in children with juvenile rheumatoid arthritis. Journal of Pediatrics, 1991, 119, 333-334.	1.8	14
222	Agreement between physicians and parents in rating functional ability of children with juvenile idiopathic arthritis. Pediatric Rheumatology, 2007, 5, 23.	2.1	14
223	A56: Macrophage Activation Syndrome in Patients With Systemic Juvenile Idiopathic Arthritis Treated With Tocilizumab. Arthritis and Rheumatology, 2014, 66, S83.	5.6	14
224	The PRINTO evidence-based proposal for glucocorticoids tapering/discontinuation in new onset juvenile dermatomyositis patients. Pediatric Rheumatology, 2019, 17, 24.	2.1	14
225	Aortic valve regurgitation as the presenting sign of Takayasu arteritis. European Journal of Pediatrics, 1999, 158, 281-283.	2.7	13
226	Uncommon Syndromes and Treatment Manifestations of Malignancy. Journal of Clinical Oncology, 2003, 21, 172-173.	1.6	13
227	Glucocorticoids in Juvenile Idiopathic Arthritis. NeuroImmunoModulation, 2015, 22, 112-118.	1.8	13
228	Comparison Between Clinical and Ultrasound Assessment of the Ankle Region in Children With Juvenile Idiopathic Arthritis. Arthritis Care and Research, 2021, 73, 1180-1186.	3.4	13
229	Performance of Birmingham Vasculitis Activity Score and disease extent index in childhood vasculitides. Clinical and Experimental Rheumatology, 2012, 30, S162-8.	0.8	13
230	Henoch-Schonlein syndrome and selective IgA deficiency.. Archives of Disease in Childhood, 1985, 60, 160-162.	1.9	12
231	Juvenile idiopathic arthritisâ€™are biologic agents effective for pain?. Nature Reviews Rheumatology, 2013, 9, 447-448.	8.0	12
232	Therapeutic approaches for the treatment of renal disease in juvenile systemic lupus erythematosus: an international multicentre PRINTO study. Annals of the Rheumatic Diseases, 2013, 72, 1503-1509.	0.9	12
233	Current Research in Outcome Measures for Pediatric Rheumatic and Autoinflammatory Diseases. Current Rheumatology Reports, 2016, 18, 8.	4.7	12
234	Is Macrophage Activation Syndrome in Kawasaki Disease Underrecognized?. Journal of Rheumatology, 2021, 48, 162-164.	2.0	12

#	ARTICLE	IF	CITATIONS
235	Pediatric Antiphospholipid Syndrome: from Pathogenesis to Clinical Management. Current Rheumatology Reports, 2021, 23, 10.	4.7	12
236	Musculoskeletal manifestations of childhood cancer and differential diagnosis with juvenile idiopathic arthritis (ONCOREUM): a multicentre, cross-sectional study. Lancet Rheumatology, The, 2021, 3, e507-e516.	3.9	12
237	Frequency and complications of chronic iridocyclitis in ANA-positive pauciarticular juvenile chronic arthritis. International Ophthalmology, 1995, 18, 225-228.	1.4	11
238	Does removal of aids/devices and help make a difference in the Childhood Health Assessment Questionnaire disability index?. Annals of the Rheumatic Diseases, 2010, 69, 82-87.	0.9	11
239	A Meta-Analysis to Estimate the Placebo Effect in Randomized Controlled Trials in Juvenile Idiopathic Arthritis. Arthritis and Rheumatology, 2016, 68, 1540-1550.	5.6	11
240	Evidence for Updating the Core Domain Set of Outcome Measures for Juvenile Idiopathic Arthritis: Report from a Special Interest Group at OMERACT 2016. Journal of Rheumatology, 2017, 44, 1884-1888.	2.0	11
241	Methotrexate treatment may prevent uveitis onset in patients with juvenile idiopathic arthritis: experiences and subgroup analysis in a cohort with frequent methotrexate use. Clinical and Experimental Rheumatology, 2016, 34, 714-8.	0.8	11
242	Development and validation of a composite disease activity score for measurement of muscle and skin involvement in juvenile dermatomyositis. Rheumatology, 2019, 58, 1196-1205.	1.9	10
243	Novel biomarkers for prediction of outcome and therapeutic response in juvenile idiopathic arthritis. Expert Review of Clinical Immunology, 2021, 17, 853-870.	3.0	10
244	IgG subclass serum levels in juvenile chronic arthritis.. Annals of the Rheumatic Diseases, 1986, 45, 400-404.	0.9	9
245	Antiphospholipid antibodies in children with idiopathic cerebral ischaemia. Lancet, The, 1994, 344, 1232.	13.7	9
246	Antiphospholipid antibody syndrome as a cause of venous thrombosis in childhood. Journal of Pediatrics, 1994, 124, 831-832.	1.8	9
247	It Is Worth Including Assessment of Disease Activity State in Juvenile Arthritis Clinical Trials. Arthritis Care and Research, 2013, 65, 1207-1210.	3.4	9
248	Frequency of Radiographic Damage and Progression in Individual Joints in Children With Juvenile Idiopathic Arthritis. Arthritis Care and Research, 2014, 66, 27-33.	3.4	9
249	The Functional Significance of Common Polymorphisms in Zinc Finger Transcription Factors. G3: Genes, Genomes, Genetics, 2014, 4, 1647-1655.	1.8	9
250	Developing a provisional, international Minimal Dataset for Juvenile Dermatomyositis: for use in clinical practice to inform research. Pediatric Rheumatology, 2014, 12, 31.	2.1	9
251	Recent therapeutic advances in juvenile idiopathic arthritis. Best Practice and Research in Clinical Rheumatology, 2017, 31, 476-487.	3.3	9
252	Recommendations for collaborative paediatric research including biobanking in Europe: a Single Hub and Access point for paediatric Rheumatology in Europe (SHARE) initiative. Annals of the Rheumatic Diseases, 2018, 77, 319-327.	0.9	9

#	ARTICLE	IF	CITATIONS
253	Macrophage activation syndrome in pediatrics. <i>Pediatric Allergy and Immunology</i> , 2020, 31, 13-15.	2.6	9
254	Serum IgG2 antibody multicomposition in systemic lupus erythematosus and lupus nephritis (Part 1): cross-sectional analysis. <i>Rheumatology</i> , 2021, 60, 3176-3188.	1.9	9
255	Weighting improves the information provided by joint counts on the severity of arthritis and its impact on patients' well-being in juvenile idiopathic arthritis. <i>Rheumatology</i> , 2006, 45, 343-347.	1.9	8
256	Acute pain management in children: a survey of Italian pediatricians. <i>Italian Journal of Pediatrics</i> , 2019, 45, 156.	2.6	8
257	Serum IgG2 antibody multi-composition in systemic lupus erythematosus and in lupus nephritis (Part) Tj ETQq1 1 0,784314 rgBT /Overlo	1.9	8
258	Treating Juvenile Idiopathic Arthritis According to JADAS-Based Targets. <i>Annals of Paediatric Rheumatology</i> , 2014, 3, 4.	0.0	8
259	Introducing new tools for assessment of parent- and child-reported outcomes in paediatric rheumatology practice: a work in progress. <i>Clinical and Experimental Rheumatology</i> , 2013, 31, 964-8.	0.8	8
260	Open issues in the assessment and management of pain in juvenile idiopathic arthritis. <i>Clinical and Experimental Rheumatology</i> , 2017, 35 Suppl 107, 123-126.	0.8	8
261	Chronic intoxication by ethane-1-hydroxy-1,1-diphosphonate (EHDP) in a child with myositis ossificans progressiva. <i>Pediatric Radiology</i> , 1993, 23, 459-462.	2.0	7
262	Growth and Puberty in Juvenile Dermatomyositis: A Longitudinal Cohort Study. <i>Arthritis Care and Research</i> , 2020, 72, 265-273.	3.4	7
263	Tocilizumab may slow radiographic progression in patients with systemic or polyarticular-course juvenile idiopathic arthritis: post hoc radiographic analysis from two randomized controlled trials. <i>Arthritis Research and Therapy</i> , 2020, 22, 211.	3.5	7
264	Thrombotic Microangiopathy Associated with Macrophage Activation Syndrome: A Multinational Study of 23 Patients. <i>Journal of Pediatrics</i> , 2021, 235, 196-202.	1.8	7
265	Recent advances in quantitative assessment of juvenile idiopathic arthritis. <i>Annals of Paediatric Rheumatology</i> , 2012, 1, 84.	0.0	7
266	Cardiovascular Manifestations in Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with COVID-19 According to Age. <i>Children</i> , 2022, 9, 583.	1.5	7
267	Urinary microscopy in the diagnosis of haematuria in schi1/2nlein-henoch purpura. <i>European Journal of Pediatrics</i> , 1986, 144, 591-593.	2.7	6
268	Macrophage activation syndrome. <i>Indian Journal of Rheumatology</i> , 2012, 7, 27-35.	0.4	6
269	Should children and adolescents with systemic lupus erythematosus be given statin therapy to prevent early atherosclerosis?. <i>Arthritis and Rheumatism</i> , 2012, 64, 33-36.	6.7	6
270	Health related quality of life measure in systemic pediatric rheumatic diseases and its translation to different languages: an international collaboration. <i>Pediatric Rheumatology</i> , 2014, 12, 49.	2.1	6

#	ARTICLE	IF	CITATIONS
271	Development of new classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. <i>Pediatric Rheumatology</i> , 2014, 12, .	2.1	6
272	Innovative Research Design to Meet the Challenges of Clinical Trials for Juvenile Dermatomyositis. <i>Current Rheumatology Reports</i> , 2018, 20, 29.	4.7	6
273	Preface. <i>Rheumatology International</i> , 2018, 38, 1-3.	3.0	6
274	Successful treatment of refractory hyperferritinemic syndromes with canakinumab: a report of two cases. <i>Pediatric Rheumatology</i> , 2020, 18, 56.	2.1	6
275	Expanding the clinical and neuroimaging features of post-varicella arteriopathy of childhood. <i>Journal of Neurology</i> , 2021, 268, 4846-4865.	3.6	6
276	Predictive Value of Magnetic Resonance Imaging in Patients With Juvenile Idiopathic Arthritis in Clinical Remission. <i>Arthritis Care and Research</i> , 2023, 75, 198-205.	3.4	6
277	Second Wave Antibodies in Autoimmune Renal Diseases: The Case of Lupus Nephritis. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 3020-3023.	6.1	6
278	Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis treated with tocilizumab. <i>Pediatric Rheumatology</i> , 2014, 12, .	2.1	5
279	Filling the Gap: Toward a Disease Activity Tool for Systemic Juvenile Idiopathic Arthritis. <i>Journal of Rheumatology</i> , 2018, 45, 3-5.	2.0	5
280	A prediction rule for lack of achievement of inactive disease with methotrexate as the sole disease-modifying antirheumatic therapy in juvenile idiopathic arthritis. <i>Pediatric Rheumatology</i> , 2019, 17, 50.	2.1	5
281	Comparison of treatments and outcomes of children with juvenile dermatomyositis followed at two European tertiary care referral centers. <i>Rheumatology</i> , 2021, 60, 5419-5423.	1.9	5
282	Underlying CTLA4 Deficiency in a Patient With Juvenile Idiopathic Arthritis and Autoimmune Lymphoproliferative Syndrome Features Successfully Treated With Abataceptâ€”A Case Report. <i>Journal of Pediatric Hematology/Oncology</i> , 2021, 43, e1168-e1172.	0.6	5
283	Canakinumab in systemic juvenile idiopathic arthritis: real-world data from a retrospective Italian cohort. <i>Rheumatology</i> , 2022, 61, 1621-1629.	1.9	5
284	Recurrent macrophage activation syndrome in spondyloarthritis and monoallelic missense mutations in PRF1: a description of one paediatric case. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, 719.	0.8	5
285	Disease activity, overweight, physical activity and screen time in a cohort of patients with juvenile idiopathic arthritis. <i>Clinical and Experimental Rheumatology</i> , 2018, 36, 1110-1116.	0.8	5
286	Anti-DNA Antibodies in the Primary Antiphospholipid Syndrome. <i>Rheumatology</i> , 1993, 32, 1028-1028.	1.9	4
287	Wegener's granulomatosis presenting with life-threatening pulmonary hemorrhage in a boy with type 1 diabetes. <i>Diabetes Care</i> , 1999, 22, 1591-1592.	8.6	4
288	A11: Assessment of Radiographic Progression in Patients With Polyarticular-Course Juvenile Idiopathic Arthritis Treated With Tocilizumab: 2-Year Data From CHERISH. <i>Arthritis and Rheumatology</i> , 2014, 66, S17-S18.	5.6	4

#	ARTICLE	IF	CITATIONS
289	What is the best definition of clinical remission in JIA?. <i>Nature Reviews Rheumatology</i> , 2017, 13, 460-461.	8.0	4
290	The Effect of Morning Stiffness Duration on the Definition of Clinically Inactive Disease in Juvenile Idiopathic Arthritis. <i>Journal of Rheumatology</i> , 2020, 47, 1238-1241.	2.0	4
291	Development and Testing of Reduced Versions of the Manual Muscle Test-8 in Juvenile Dermatomyositis. <i>Journal of Rheumatology</i> , 2021, 48, 898-906.	2.0	4
292	The challenge of early diagnosis of autoimmune lymphoproliferative syndrome in children with suspected autoinflammatory/autoimmune disorders. <i>Rheumatology</i> , 2021, , .	1.9	4
293	Type I interferon activation in RAS-associated autoimmune leukoproliferative disease (RALD). <i>Clinical Immunology</i> , 2021, 231, 108837.	3.2	4
294	Evaluation of Biopsychosocial Aspects of Patients with Juvenile Autoinflammatory Disease: A Qualitative Study. <i>Annals of Paediatric Rheumatology</i> , 2014, 3, 62.	0.0	4
295	Childhood multisystem inflammatory syndrome associated with COVID-19 (MIS-C): Distinct from Kawasaki disease or part of the same spectrum?. <i>Pediatric Allergy and Immunology</i> , 2022, 33, 102-104.	2.6	4
296	The invisible part of the iceberg: qualitative aspects of childhood vasculitis. <i>Clinical and Experimental Rheumatology</i> , 2014, 32, S122-7.	0.8	4
297	Information technology in paediatric rheumatology. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, S11-S16.	0.8	4
298	Visceral leishmaniasis as a cause of unexplained fever and cytopenia in systemic lupus erythematosus. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 2002, 91, 246-247.	1.5	4
299	Agreement Among Musculoskeletal Pediatric Specialists in the Assessment of Radiographic Joint Damage in Juvenile Idiopathic Arthritis. <i>Arthritis Care and Research</i> , 2014, 66, 34-39.	3.4	3
300	Determinants of discordance between criteria for inactive disease and low disease activity in juvenile idiopathic arthritis. <i>Arthritis Care and Research</i> , 2020, 73, 1722-1729.	3.4	3
301	Agreement between multi-dimensional and renal-specific response criteria in patients with juvenile systemic lupus erythematosus and renal disease. <i>Clinical and Experimental Rheumatology</i> , 2010, 28, 424-33.	0.8	3
302	Periostin gene variants are associated with disease course and severity in juvenile idiopathic arthritis. <i>Clinical and Experimental Rheumatology</i> , 2014, 32, 747-53.	0.8	3
303	Drivers of non-zero physician global scores during periods of inactive disease in juvenile idiopathic arthritis. <i>RMD Open</i> , 2022, 8, e002042.	3.8	3
304	Variation of serum IgG subclass concentrations with disease activity in juvenile chronic arthritis.. <i>Annals of the Rheumatic Diseases</i> , 1989, 48, 582-585.	0.9	2
305	The Long-Term Outcome of Juvenile Idiopathic Arthritis. <i>Current Rheumatology Reviews</i> , 2005, 1, 151-155.	0.8	2
306	Sensitivity and specificity of current diagnostic guidelines in children with macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. <i>Pediatric Rheumatology</i> , 2011, 9, .	2.1	2

#	ARTICLE	IF	CITATIONS
307	A66: Assessment of Radiographic Progression in Patients With Systemic Juvenile Idiopathic Arthritis Treated With Tocilizumab: 2-Year Results From the TENDER Trial. Arthritis and Rheumatology, 2014, 66, S96.	5.6	2
308	The Italian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 251-258.	3.0	2
309	Fostering the application of the MS score in systemic juvenile idiopathic arthritis. Response to: "MS score in systemic juvenile idiopathic arthritis: suitable for routine use?" by Chi et al. Annals of the Rheumatic Diseases, 2019, 80, annrheumdis-2019-216067.	0.9	2
310	Update on Outcome Measures for Pediatric Systemic Lupus Erythematosus. Arthritis Care and Research, 2020, 72, 163-170.	3.4	2
311	Response to: "Comparison of MS score and HScore for the diagnosis of adult-onset Still's disease associated macrophage activation syndrome" by Zhang et al. Annals of the Rheumatic Diseases, 2022, 81, e100-e100.	0.9	2
312	The controversial role of wellbeing assessment in juvenile idiopathic arthritis. Lancet Rheumatology, The, 2021, 3, e85-e86.	3.9	2
313	Management of Patients with Juvenile Idiopathic Arthritis. , 2016, , 87-114.		2
314	Multifactorial Posterior Reversible Encephalopathy Syndrome in Children: Clinical, Laboratory, and Neuroimaging Findings. Journal of Pediatric Neurology, 2021, 19, 083-091.	0.2	2
315	Validity and reliability of four parent/patient reported outcome measures for juvenile idiopathic arthritis remote monitoring. Arthritis Care and Research, 2022, , .	3.4	2
316	Transitional care of young people with juvenile idiopathic arthritis in Italy: results of a Delphi consensus survey. Clinical and Experimental Rheumatology, 2019, 37, 1084-1091.	0.8	2
317	Analysis of arthritis flares after achievement of inactive disease with methotrexate monotherapy in juvenile idiopathic arthritis. Clinical and Experimental Rheumatology, 2021, 39, 426-433.	0.8	2
318	Reply to letter by Isenberg and Gordon commenting on the Pediatric Rheumatology International Trials Organization criteria for the evaluation of response to therapy in juvenile systemic lupus erythematosus. Arthritis and Rheumatism, 2006, 54, 3723-3724.	6.7	1
319	Chapter 4 Macrophage Activation Syndrome. Handbook of Systemic Autoimmune Diseases, 2007, , 55-275.	0.1	1
320	Macrophage Activation Syndrome in Childhood Rheumatic Diseases. Current Rheumatology Reviews, 2007, 3, 225-230.	0.8	1
321	Section 4: Juvenile Idiopathic Arthritis. Clinical Drug Investigation, 2013, 33, 133-137.	2.2	1
322	A30: Assessment of Construct and Discriminative Validity of the 3-Variable JADAS in Relation of Parent-Reported Outcomes. Arthritis and Rheumatology, 2014, 66, S46-S46.	5.6	1
323	Dr. Tibaldi, et al reply. Journal of Rheumatology, 2019, 46, 1424-1424.	2.0	1
324	Response to "Application of MS score in macrophage activation syndrome patients associated with adult onset Still's disease" by Wang et al. Annals of the Rheumatic Diseases, 2021, 80, e146-e146.	0.9	1

#	ARTICLE	IF	CITATIONS
325	Consequences and complications. , 2016, , 59-71.		1
326	General treatment aspects. , 2016, , 73-85.		1
327	Medicine and humanism in the time of COVID-19. Ethical choices. Acta Biomedica, 2020, 91, e2020167.	0.3	1
328	Neonatal lupus erythematosus in dizygotic twins with anti-RNP antibodies. Clinical and Experimental Rheumatology, 2021, 39, 1446.	0.8	1
329	Systemic Vasculitis Followed by Chronic Myelogenous Leukemia. Pediatric Hematology and Oncology, 1988, 5, 315-318.	0.8	0
330	Sensitivity and specificity of current diagnostic guidelines in children with macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. Pediatric Rheumatology, 2011, 9, .	2.1	0
331	Proposal for the development of an international minimal data collection for juvenile dermatomyositis (JDM). Pediatric Rheumatology, 2011, 9, P51.	2.1	0
332	Is it worth including subtalar joint in ultrasound ankle assessment of patients with juvenile idiopathic arthritis?. Pediatric Rheumatology, 2014, 12, .	2.1	0
333	Is it worth allowing the presence of morning stiffness in the definition of inactive disease in juvenile idiopathic arthritis?. Pediatric Rheumatology, 2014, 12, .	2.1	0
334	Nearly 20% of children are not correctly classified according to current ilar classification in a PRINTO dataset of more than 12,000 juvenile idiopathic arthritis patients. Pediatric Rheumatology, 2014, 12, .	2.1	0
335	The PRINTO juvenile dermatomyositis trial â€œ Authors' reply. Lancet, The, 2016, 387, 2601.	13.7	0
336	THU0515â€¦PAIN IS THE MAIN DETERMINANT OF WELL-BEING IN OLIGO- AND POLYARTICULAR JIA: EVIDENCE FROM THE PHARMACHILD REGISTRY. , 2019, , .		0
337	Evaluation of musculoskeletal complaints in children. , 2015, , 815-819.		0
338	Disease classification. , 2016, , 17-24.		0
339	Macrophage Activation Syndrome. , 2017, , 275-292.		0
340	Criteria for Cytokine Storm Syndromes. , 2019, , 61-79.		0
341	Analysis of arthritis flares after achievement of inactive disease with methotrexate monotherapy in juvenile idiopathic arthritis. Clinical and Experimental Rheumatology, 2021, 39, 426-433.	0.8	0
342	A prediction rule for polyarticular extension in oligoarticular-onset juvenile idiopathic arthritis. Clinical and Experimental Rheumatology, 2021, 39, 913-919.	0.8	0

#	ARTICLE	IF	CITATIONS
343	2021 ACR guideline for JIA reflects changes in practice. Nature Reviews Rheumatology, 2022, , .	8.0	0